Sep 20, 2021 8:00am EDT Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results
Sep 13, 2021 3:58pm EDT Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference
Sep 08, 2021 8:10am EDT Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022
Sep 08, 2021 8:05am EDT Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals
Sep 08, 2021 8:00am EDT Benitec Biopharma Provides Positive Regulatory Updates for the BB-301 Development Program; BB-301 Phase 1b/2a Clinical Trial to Begin in 2022
Apr 27, 2021 9:55pm EDT Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million
Apr 27, 2021 4:44pm EDT Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock
Feb 24, 2021 8:29am EST Benitec Biopharma Announces Successful Results from the Interim Analysis of the BB-301 Pilot Dosing Study
Oct 06, 2020 4:05pm EDT Benitec Biopharma Announces Closing of $11.5 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
